公开(公告)号：US20180292410A1

公开(公告)日：2018-10-11

申请号：US16008550

申请日：2018-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Friedemann Krause ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Vinzent Rolny ,  Sandra Rutz ,  Thomas Muley ,  Felix Herth ,  Julia Riedlinger

IPC: G01N33/574

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.

公开(公告)号：US20230366894A1

公开(公告)日：2023-11-16

申请号：US18028235

申请日：2021-09-30

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Jennifer Marie Theresia Anna Meessen ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler

IPC: G01N33/74

CPC classification number: G01N33/74 ,  G01N2333/58 ,  G01N2440/38 ,  G01N2800/326

Abstract: The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.

公开(公告)号：US20230305010A1

公开(公告)日：2023-09-28

申请号：US18309985

申请日：2023-05-01

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Anika Mang ,  David Morgenstern ,  Vinzent Rolny ,  Magdalena Swiatek-De Lange

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N2333/8146 ,  G01N2333/96494 ,  G01N2470/04 ,  G01N2800/50 ,  G01N2800/08

Abstract: The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.

公开(公告)号：US20230296630A1

公开(公告)日：2023-09-21

申请号：US18021021

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Michael Kuehne ,  Stefan Osswald

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/2814

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210239712A1

公开(公告)日：2021-08-05

申请号：US17181390

申请日：2021-02-22

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.

公开(公告)号：US20210172962A1

公开(公告)日：2021-06-10

申请号：US17172761

申请日：2021-02-10

Applicant: Roche Diagnostics Operations, Inc. ,  UNIVERSITEIT MAASTRICHT ,  AKADEMISCH ZIEKENHUIS MAASTRICHT

Inventor： Manuel Dietrich ,  Peter Kastner ,  Vinzent Rolny ,  Ulrich Schotten ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.

公开(公告)号：US20170227552A1

公开(公告)日：2017-08-10

申请号：US15581587

申请日：2017-04-28

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Roberto Latini ,  Serge Masson ,  Dirk Block ,  Christian Zaugg ,  Thomas Dieterle ,  Edelgard Kaiser ,  Johann Karl ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68

Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.

公开(公告)号：US20250138017A1

公开(公告)日：2025-05-01

申请号：US18930774

申请日：2024-10-29

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Holger Busskamp ,  Konstantin Kroeniger ,  Mahdokht Kohansal Nodehi ,  Magdalena Swiatek-de Lange ,  Gloria Tabares

IPC: G01N33/574 ,  G01N33/68

Abstract: The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and/or PIVKA-II in the detection of HCC.

公开(公告)号：US20250116670A1

公开(公告)日：2025-04-10

申请号：US18908787

申请日：2024-10-07

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Christa Cobbaert ,  Konstantin Kroeniger ,  Guinevere Lageveen-Kammeijer ,  Jan Nouta ,  Vinzent Rolny ,  Renee Ruhaak ,  Magdalena Swiatek-de Lange ,  Gloria Tabares ,  Yuri van der Burgt ,  Manfred Wuhrer

IPC: G01N33/574 ,  G01N33/573

Abstract: The present invention relates to methods for assessing whether or not a patient has aggressive prostate cancer by determining the levels of particular glycoforms attached to prostate specific antigen (PSA) protein in a biofluid sample of a subject, and comparing the determined level or concentration to a reference. The methods are particularly useful for assessing subjects that have 2-10 ng/ml total PSA in the subject's serum.

公开(公告)号：US11946938B2

公开(公告)日：2024-04-02

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4745 ,  G01N2333/515 ,  G01N2800/326 ,  G01N2800/50

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.